PDF下载 ( 1468 KB)
Research advances in receptor and inhibitors of hepatitis B virus entry
-
摘要: 钠离子/牛磺胆酸共转运多肽(NTCP)是HBV感染的受体。HBV受体的发现为抗HBV新药研发提供了新靶标。阐述了HBV感染研究中遇到的瓶颈、NCTP的发现意义及其表达调节,通过近2年来的研究,发现许多药物可以阻断NTCP的受体功能,进而高效阻断HBV感染,认为HBV进入抑制剂已成为抗HBV新药研发的主流,并且有可能成为未来根治慢性乙型肝炎的策略之一。
-
关键词:
- 肝炎病毒,乙型 /
- 有机阴离子转运子,钠依赖 /
- 进入抑制剂 /
- 综述
Abstract: Sodium taurocholate cotransporting polypeptide( NTCP) was identified as the receptor for hepatitis B virus( HBV) infection in2012. The finding of HBV receptor has provided a new target for the development of new anti- HBV drugs. This article describes the bottleneck of research on HBV infection,as well as the significance of the finding of HBV and its expression regulation. Over the past two years,studies have shown that a variety of agents can block the receptor function of NTCP and then inhibit HBV entry efficiently. The inhibitors of HBV entry have become a major concept in the development of new anti- HBV drugs and may be one of future strategies for radical treatment of chronic hepatitis B. -
本文二维码
计量
- 文章访问数: 2135
- HTML全文浏览量: 15
- PDF下载量: 583
- 被引次数: 0
下载:
